reconsideration. Petitions to stay that do not involve environmental issues,² formal expressions of intent to file an OFA under 49 CFR 1152.27(c)(2),³ and trail use/rail banking requests under 49 CFR 1152.29 must be filed by August 6, 2007. Petitions to reopen or requests for public use conditions under 49 CFR 1152.28 must be filed by August 16, 2007, with the Surface Transportation Board, 395 E Street, SW., Washington, DC 20423–0001.

A copy of any petition filed with the Board should be sent to CSXT's representative: Steven C. Armbrust, Esq., CSX Transportation, Inc., 500 Water Street, J–150, Jacksonville, FL 32202.

If the verified notice contains false or misleading information, the exemption is void *ab initio*.

CSXT has filed environmental and historic reports addressing the effects, if any, of the abandonment on the environment and historic resources. SEA will issue an environmental assessment (EA) by August 3, 2007. Interested persons may obtain a copy of the EA by writing to SEA (Room 1100, Surface Transportation Board, Washington, DC 20423-0001) or by calling SEA, at (202) 245-0305. [Assistance for the hearing impaired is available through the Federal Information Relay Service (FIRS) at 1-800-877-8339.] Comments on environmental and historic preservation matters must be filed within 15 days after the EA becomes available to the public.

Environmental, historic preservation, public use, or trail use/rail banking conditions will be imposed, where appropriate, in a subsequent decision.

Pursuant to the provisions of 49 CFR 1152.29(e)(2), CSXT shall file a notice of consummation with the Board to signify that it has exercised the authority granted and fully abandoned the line. If consummation has not been effected by CSXT's filing of a notice of consummation by July 27, 2008, and there are no legal or regulatory barriers to consummation, the authority to abandon will automatically expire.

Board decisions and notices are available on our Web site at: http://www.stb.dot.gov.

Decided: July 23, 2007.

By the Board, David M. Konschnik, Director, Office of Proceedings.

Vernon A. Williams,

Secretary.

[FR Doc. E7–14440 Filed 7–26–07; 8:45 am] BILLING CODE 4915–01–P

DEPARTMENT OF VETERANS AFFAIRS

Veterans' Disability Benefits Commission; Notice of Meetings

The Department of Veterans Affairs (VA) gives notice under Public Law 92-463 (Federal Advisory Committee Act) that the Veterans' Disability Benefits Commission will hold meetings on August 8-10, 2007 and August 22-24, 2007, at the Hotel Washington, 15th Street and Pennsylvania Avenue, NW., Washington, DC. On August 8 and August 22, the sessions will begin at 10 a.m. and end at 4:30-5:30 p.m. On August 9 and August 23, the sessions will begin at 8:30 a.m. and end at 4:30-5:30 p.m. On August 10 and August 24, the sessions will begin at 8:30 a.m. and end at 12 noon-3 p.m. depending on the final agenda for each session. Each meeting is open to the public.

The purpose of the Commission is to carry out a study of the benefits under the laws of the United States that are provided to compensate and assist veterans and their survivors for disabilities and deaths attributable to military service.

The agenda for the first August meeting will feature the final report of the Center of Naval Analyses (CNA) and a report of the Institute of Medicine (IOM) Committee on Presumptions. The Commission will review technical comments from VA and make final decisions on three Issues Papers related to specific Research Questions approved by the Commission on October 14, 2005. The topics will be: Transition Issues (addressing Research Questions 26-31), Vocational Rehabilitation and Employment (Research Question 17), and Ancillary and Special Purpose Benefits (Research Question 20). VA and the Department of Defense (DoD) will respond to the report of the IOM Committee on Medical Evaluation of Veterans for Disability, and the Commission will decide its position on the two IOM studies and recommendations made to VA on the topic of Post-Traumatic Stress Disorder (PTSD). Additional discussions and

potential decisions will be reached on options to achieve equity in lifetime benefits, integrating the findings of various studies and research projects conducted for the Commission, and drafting the Commission's final report.

The agenda for the second August meeting will be devoted to drafting the Commission's final report and may include a limited number of clarifying presentations on topics the Commission requires to complete its final report.

There will be time set aside at each meeting for public comments. Interested persons may attend and present oral statements to the Commission on August 8 or August 22. Oral presentations will be limited to five minutes or less. Interested parties may also provide written comments for review by the Commission prior to the meeting or at any time, by e-mail to veterans@vetscommission.com or by mail to Mr. Ray Wilburn, Executive Director, Veterans' Disability Benefits Commission, 1101 Pennsylvania Avenue, NW., 5th Floor, Washington, DC 20004.

Dated: July 23, 2007. By direction of the Secretary:

E. Philip Riggin,

Committee Management Officer. [FR Doc. 07–3675 Filed 7–26–07; 8:45 am] BILLING CODE 8320–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Clinical Laboratory Improvement Advisory Committee (CLIAC)

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following meeting for the aforementioned committee:

Times and Dates:

8:30 a.m.–5 p.m., September 5, 2007. 8:30 a.m.–3 p.m., September 6, 2007. Place: CDC, 1600 Clifton Road, NE., Tom Harkin Global Communications Center, Building 19, Room 232, Auditorium B, Atlanta, Georgia 30333.

Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 100 people.

Purpose: This Committee is charged with providing scientific and technical advice and guidance to the Secretary of Health and Human Services, the Assistant Secretary for Health, and the Director, CDC, regarding the need for, and the nature of, revisions to the standards under which clinical laboratories are regulated; the impact on medical and laboratory practice of proposed revisions to

² The Board will grant a stay if an informed decision on environmental issues (whether raised by a party or by the Board's Section of Environmental Analysis (SEA) in its independent investigation) cannot be made before the exemption's effective date. See Exemption of Outof-Service Rail Lines, 5 I.C.C.2d 377 (1989). Any request for a stay should be filed as soon as possible so that the Board may take appropriate action before the exemption's effective date.

³ Each OFA must be accompanied by the filing fee, which currently is set at \$1,300. See 49 CFR 1002.2(f)(25).

the standards; and the modification of the standards to accommodate technological advances.

Matters To Be Discussed: The agenda will include updates from the CDC, the Centers for Medicare & Medicaid Services, and the Food and Drug Administration; presentations and discussions on current and planned CLIAC Research; an overview of the September 2007 Institute for Critical Issues in Health Laboratory Practice: Managing for Better Health; an update on oversight of Genetic Testing; and an Introduction to Quality Management Systems for the Clinical Laboratory. Agenda items are subject to change as priorities dictate.

New Information—Online Registration Required: In order to expedite security clearance process at the CDC Roybal Campus located on Clifton Road, all CLIAC attendees are required to register for the meeting online at least 30 days in advance at http://wwwn.cdc.gov/cliac/default.aspx, by clicking the "Register for Meeting" link; complete the form and click "submit." Please complete all required fields before submitting your registration and submit no later than August 5, 2007.

Providing Oral or Written Comments: It is CLIAC policy to accept written public comments and provide a brief period for oral public comments whenever possible. Oral Comments: In general, each individual or group requesting to make an oral presentation will be limited to a total time of five minutes (unless otherwise indicated). Speakers must also submit their comments in writing for inclusion in the meeting summary report. To assure adequate time is scheduled for public comments, individuals or groups planning to make an oral presentation should notify the contact person below at least one week prior to the meeting date. Written Comments: For individuals or groups unable to attend the meeting, CLIAC accepts written comments until the date of the meeting (unless otherwise stated). However, the comments should be received at least one week prior to the meeting date so that the comments may be made available to the committee for their consideration and public distribution. Written comments should be on hard copy with original signature provided to the contact person below. Written comments will be included in the meeting summary report.

Contact Person for Additional Information: Nancy Anderson, Acting Chief, Laboratory Practice Standards Branch, Division of Laboratory Systems, National Center for Preparedness, Detection, and Control of Infectious Diseases, Coordinating Center for Infectious Diseases, CDC, 1600 Clifton Road, NE., Mailstop F–11, Atlanta, Georgia 30333; telephone (404) 718–1025; fax (404) 718–1085; or via e-mail at Nancy.Anderson@cdc.hhs.gov.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** Notices pertaining to announcements of meetings and other committee management activities, for CDC and the Agency for Toxic Substances and Disease Registry.

Dated: July 23, 2007.

Elaine L. Baker,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. E7–14571 Filed 7–26–07; 8:45 am] BILLING CODE 4163–18–P